Description du projet
De nouveaux vaccins et diagnostics pour améliorer la santé et la productivité des animaux
Les maladies infectieuses endémiques et zoonotiques de la reproduction du bétail peuvent causer des pertes économiques importantes et menacer la sécurité alimentaire et la santé publique. Le projet REPRODIVAC, financé par l’UE, abordera ce problème. Réunissant un consortium d’experts issus du monde universitaire et de l’industrie disposant d’une expérience diversifiée en biologie structurale, microbiologie, immunologie, sciences végétales et sciences vétérinaires, le projet utilisera une approche interdisciplinaire pour développer de nouveaux vaccins et outils de diagnostic améliorés pour les maladies qui affectent le bétail comme les porcs, les moutons et les chèvres. Le projet se concentrera sur le développement d’un vaccin protecteur contre le syndrome reproducteur et respiratoire porcin, de candidats vaccins sous-unités contre la fièvre Q, d’un vaccin raffiné contre l’avortement enzootique ovin, de vaccins vivants atténués contre Brucella suis et de tests de diagnostic améliorés.
Objectif
Endemic and zoonotic infectious reproductive diseases of livestock cause major economic losses globally and threaten both food security and public health. REPRODIVAC will develop new and improved vaccines and diagnostic tools required to better control four priority abortifacient diseases: porcine reproductive and respiratory syndrome (PRRS), Q fever, ovine enzootic abortion (OEA), and porcine brucellosis. The consortium spans academia and industry with complementary expertise including structural biology, microbiology, immunology, plant and veterinary sciences. This enables us to address reproductive disorders with an interdisciplinary approach: (1) applying reverse and structural vaccinology to select and design vaccine and diagnostic candidate antigens; (2) exploiting relevant protein expression systems for the production of these antigens; (3) producing rationally attenuated and viral vectored vaccines; and (4) developing a suite of molecular and immunological diagnostic tests, including point-of-care tests (PoC) to discriminate vaccinated from infected animals (DIVA). We will develop a broadly protective PRRSV vaccine, and a serological ELISA that will reliably correlate with PRRSV neutralising antibody titres. We will identify protective subunit vaccine candidates for Q fever and validate a companion serological DIVA test. We will further refine an OEA vaccine for commercialisation and pursue a complementary approach towards a DIVA-compatible next-generation subunit vaccine and serological and molecular DIVA/PoC tests. We will develop live attenuated Brucella suis vaccines and brucellosis diagnostic tests with improved specificity. These new vaccines and diagnostics will be further developed by our industrial partners and made accessible to users. Thereby by using the latest technologies in vaccine and diagnostic development REPRODIVAC will improve animal health and welfare, productivity and sustainability of the livestock sector, as well as human health.
Champ scientifique
Mots‑clés
Programme(s)
Régime de financement
HORIZON-IA - HORIZON Innovation ActionsCoordinateur
00196 Roma
Italie